EZH2 and prostate cancer: Since DNA and histone hypermethylation has been linked to carcinogenesis, and the overexpression of EZH2 was found in numerous cancer forms, including breast cancer, prostate cancer, leukemia and pancreatic tumors, this has been considered to be a potential cancer therapy target [29–32].